Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

Susanna Esposito, Lorenza Pugni, Cristina Daleno, Andrea Ronchi, Antonia Valzano, Domenico Serra, Fabio Mosca, Nicola Principi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: This study was designed to evaluate the immunogenicity, safety, and tolerability of a monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children aged 6 to 23 months who had different gestational ages (GAs) at birth. METHODS: The study involved 105 children: 35 preterm subjects with a GA of

Original languageEnglish
JournalPediatrics
Volume127
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • A/H1N1 influenza vaccine
  • Adjuvants
  • MF59
  • Pandemic influenza
  • Preterm infants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months'. Together they form a unique fingerprint.

  • Cite this